Prolactin response to D-fenfluramine challenge test as a predictor of treatment response to haloperidol in acute schizophrenia

Schizophrenia Research
P MohrP Czobor

Abstract

D-fenfluramine has been identified as a highly selective serotonin (5-HT) releaser and re-uptake inhibitor. The objective of our study was to investigate prolactin response to D-fenfluramine challenge in non-medicated, first episode schizophrenics. We hypothesized that 5-HT reactivity can predict a response to the neuroleptic treatment. Twenty-three inpatients, 11 males and 12 females, at the Prague Psychiatric Center participated in the study. Inclusion criteria were: ICD-10 diagnosis of schizophrenia, first episode or duration of illness shorter than 36 months. D-fenfluramine challenge test was performed before 4 weeks of the haloperidol treatment. During the test, prolactin plasma levels were measured. The Brief Psychiatric Rating Scale (BPRS) was administered before and after the treatment. A statistically significant negative correlation was found between prolactin response to the D-fenfluramine challenge and improvement of psychopathology measured by the change in total BPRS score (p = 0.0004), in positive (p = 0.0403), negative (p = 0.0267), and anxiety-depression symptoms of BPRS (p = 0.0014). Our data support the original hypothesis that there is a relationship between 5-HT system activity and treatment response. The h...Continue Reading

References

Feb 1, 1991·Archives of General Psychiatry·A RifkinM Wachspress
Dec 4, 1990·Klinische Wochenschrift·G BenkerD Reinwein
May 19, 1989·European Journal of Pharmacology·R InvernizziR Samanin
Jan 1, 1988·Archives of General Psychiatry·R J BaldessariniM H Teicher
Jan 1, 1988·Schizophrenia Bulletin·A BleichH M van Praag
Jan 1, 1987·Biological Psychiatry·H M van PraagR Kahn
Jun 1, 1994·The American Journal of Psychiatry·S R Marder, R C Meibach
Feb 1, 1995·Schizophrenia Research·A Breier
Apr 1, 1995·Psychopharmacology·S B Park, P J Cowen
Oct 1, 1995·Archives of General Psychiatry·J VolavkaM Meisner
May 1, 1995·The British Journal of Psychiatry : the Journal of Mental Science·V A CurtisJ V Lucey
Feb 1, 1994·Journal of Affective Disorders·G M GoodwinJ Bancroft
Jan 1, 1994·The American Journal of Psychiatry·A BreierW T Carpenter
Jan 1, 1993·Life Sciences·L N Yatham, M Steiner
Jan 1, 1993·International Clinical Psychopharmacology·S FeeneyT Silverstone
Jan 1, 1996·The British Journal of Psychiatry : the Journal of Mental Science·K M AbelR M Murray
Jan 1, 1995·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·N Iqbal, H M van Praag
Dec 1, 1996·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·E F CoccaroR L Hauger
Jan 1, 1997·The Journal of Neuropsychiatry and Clinical Neurosciences·A Abi-DarghamJ Krystal

❮ Previous
Next ❯

Citations

Aug 22, 2002·Progress in Neuro-psychopharmacology & Biological Psychiatry·Eva CeskováMiroslav Lorenc
Jun 27, 2002·Schizophrenia Research·Humberto CorrêaJean-Paul Macher
May 7, 2014·Schizophrenia Research and Treatment·Ravi Philip Rajkumar
Nov 16, 2004·Annals of the New York Academy of Sciences·Masaomi IyoNorio Mori
Jul 12, 2002·International Journal of Geriatric Psychiatry·Krista L LanctôtClaudio A Naranjo
Nov 27, 2009·Journal of Psychopharmacology·James M StonePhilip K McGuire
Jan 5, 2002·Journal of Clinical Psychopharmacology·F E ScheepersR S Kahn
Feb 18, 2017·Singapore Medical Journal·Chung Wai Mark NgYin Ping Ng

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here